Table 3

Risk of Vascular Events by HDL-C According to LDL-C Level

LDL-C (mmol/l)<2.02.0 to <2.52.5 to <3.03.0 to <4.0≥4.0
Lipid-lowering therapy1,027 (79)997 (84)861 (88)803 (123)250 (42)
 Model 11.01 (0.95–1.07)0.96 (0.90–1.03)0.97 (0.91–1.04)0.90 (0.84–0.96)0.93 (0.84–1.04)
 Model 21.00 (0.94–1.07)0.97 (0.90–1.04)0.98 (0.91–1.06)0.91 (0.84–0.98)0.94 (0.85–1.06)
 Model 31.02 (0.95–1.09)0.97 (0.90–1.05)1.01 (0.94–1.09)0.92 (0.86–0.99)0.96 (0.86–1.07)
No lipid-lowering therapy297 (43)301 (46)812 (180)737 (183)
 Model 10.95 (0.87–1.03)0.97 (0.90–1.05)0.95 (0.90–1.00)0.94 (0.89–0.99)
 Model 20.94 (0.85–1.03)0.97 (0.90–1.06)0.97 (0.91–1.02)0.93 (0.88–0.99)
 Model 30.94 (0.86–1.04)0.98 (0.90–1.07)0.97 (0.92–1.02)0.94 (0.89–1.00)

Values are n (events) or hazard ratio (95% confidence interval) per 0.1 mmol/l increase in HDL-C, stratified for LDL-C level separately for use of lipid-lowering therapy. For patients using no lipid-lowering therapy, few patients (n = 124) had LDL-C levels <2.0 mmol/l; therefore, these patients were added to the patients with LDL-C levels of 2.0 to <2.5 mmol/l. Model 1: Adjusted for age and sex. Model 2: Model 1 + type 2 diabetes mellitus, body mass index, and plasma triglyceride levels. Model 3: Model 2 + smoking and alcohol.

Abbreviations as in Table 1.